Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
5(100.0%)
5Total
Phase 2(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT03322865Phase 2Active Not Recruiting

Obinutuzumab in Marginal Zone Lymphoma

Role: lead

NCT03474744Phase 2Active Not Recruiting

Copanlisib and Rituximab in Marginal Zone Lymphoma Patients

Role: lead

NCT05099471Phase 2Recruiting

Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia

Role: lead

NCT03620903Phase 2Active Not Recruiting

Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia

Role: lead

NCT04263480Phase 2Active Not Recruiting

Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia

Role: lead

All 5 trials loaded